Kenvue (NYSE:KVUE) Stock Rating Lowered by Zacks Research

by · The Cerbat Gem

Kenvue (NYSE:KVUE – Get Free Report) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

KVUE has been the topic of a number of other research reports. UBS Group lowered their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Citigroup reduced their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. Barclays lowered their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Finally, Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Three research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $19.33.

View Our Latest Report on KVUE

Kenvue Price Performance

Kenvue stock opened at $19.28 on Tuesday. Kenvue has a 52-week low of $14.02 and a 52-week high of $22.87. The firm has a market capitalization of $37.01 billion, a price-to-earnings ratio of 22.68, a PEG ratio of 1.50 and a beta of 0.47. The company has a fifty day simple moving average of $17.98 and a 200-day simple moving average of $17.76. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period last year, the firm posted $0.24 earnings per share. On average, equities analysts anticipate that Kenvue will post 1.16 EPS for the current fiscal year.

Insider Transactions at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.59% of the company’s stock.

Institutional Trading of Kenvue

A number of institutional investors and hedge funds have recently bought and sold shares of KVUE. Physician Wealth Advisors Inc. boosted its stake in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the period. Elyxium Wealth LLC purchased a new stake in Kenvue during the 4th quarter worth approximately $26,000. MV Capital Management Inc. purchased a new stake in Kenvue during the 4th quarter worth approximately $28,000. CoreCap Advisors LLC lifted its holdings in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares in the last quarter. Finally, Reflection Asset Management purchased a new position in Kenvue in the 4th quarter valued at approximately $32,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Kenvue

(Get Free Report)

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

Further Reading